http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-114010666-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d9de52bba13e16028dffa8775e3f3f28 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-16621 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-53 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-502 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-3955 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-63 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-763 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N7-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N7-01 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-763 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-63 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-502 |
| filingDate | 2021-10-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_59ed25ab86e73f6a7415974605946256 |
| publicationDate | 2022-02-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-114010666-A |
| titleOfInvention | Application of oncolytic virus, PARP inhibitor and PD-1 antibody in preparation of antitumor drugs |
| abstract | The invention provides an application of an oncolytic virus, a PARP inhibitor and a PD-1 antibody in preparing an anti-tumor medicament, wherein miRT124 and hGMCSF are inserted into a type I herpes simplex virus to obtain an oncolytic virus oHSV, so that the safety of the oncolytic virus is improved, and the immune response of an organism is enhanced; through the combined use of the oncolytic virus oHSV and the Olaparib, the PD-1 expression quantity of the CD4+ T cell and the CD8+ T cell can be increased by combining the oncolytic virus oHSV and the Olaparib, so that an immune checkpoint inhibitor, namely a PD-1 antibody is introduced, the curative effect of a treatment scheme in breast cancer is further improved, the size of an in-situ tumor of the breast cancer of a mouse is further inhibited by combining the oHSV, the Olaparib and the PD-1 antibody, on the basis of the combined use of the oHSV, the Olaparib and the PD-1 antibody, the number of lung metastasis foci is further reduced, and the survival period of the mouse is remarkably prolonged. |
| priorityDate | 2021-10-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 97.